Respiratory Tuberculosis Clinical Trial
Official title:
A Multicenter Clinical Trial of Recombinant Human Interferon Gamma (Ingaron) in Pulmonary Tuberculosis
The main purpose of testing: To confirm the effectiveness and safety of the drug Ingaron when used in patients hospitalized at the research center for various reasons.
Monitoring of a patient in a hospital is carried out daily by the attending physician during the entire period of the patient's stay at the research center. When prescribing the drug Ingaron, the researcher must follow the instructions for use of the drug. As part of 4 control observations to assess effectiveness and safety: - 1st on the 1st day of using the drug Ingaron and starting anti-tuberculosis therapy - 2nd on the 30th - 31st day of therapy - 3rd after 2 months of therapy - 4th (final) after 3 months of follow-up After each of the 3 visits, the research doctor saves the data necessary for further evaluation. ;